https://www.onclive.com/view/manuever-trial-underscores-potential-paradigm-shift-toward-targeted-approaches-in-tgct2026-05-06T23:13:01.078Z2026-05-06T23:13:01.078Z https://www.onclive.com/view/dr-mcgregor-on-the-dad-io-trial-of-sacituzumab-govitecan-and-ev-in-metastatic-urothelial-carcinoma2026-05-06T19:22:31.509Z2026-05-06T19:22:31.509Z https://www.onclive.com/view/neoadjuvant-t-dxd-followed-by-thp-improves-rcb-in-her2-breast-cancer2026-05-06T19:16:58.298Z2026-05-06T19:16:58.298Z https://www.onclive.com/view/dr-lee-on-research-collaborations-studying-pd-l1-as-a-biomarker-in-nsclc2026-05-06T19:00:00Z2026-05-06T19:00:00Z https://www.onclive.com/view/dr-chari-on-frontline-combinations-and-transplant-approaches-in-multiple-myeloma2026-05-06T18:58:54.072Z2026-05-06T18:58:54.072Z https://www.onclive.com/view/fda-accepts-snda-for-taletrectinib-in-ros1-nsclc2026-05-06T17:36:48.389Z2026-05-06T17:36:48.389Z https://www.onclive.com/view/cases-and-conversations-next-generation-pathology-advances-and-considerations-for-precision-care-in-non-small-cell-lung-cancer2026-05-06T16:55:15.505Z2026-05-06T16:55:15.505Z https://www.onclive.com/view/dr-herrera-on-the-significance-of-the-fda-approval-of-nivolumab-plus-avd-for-classical-hodgkin-lymphoma2026-05-06T16:36:20.819Z2026-05-06T16:36:20.819Z https://www.onclive.com/view/dr-sznol-on-biomarkers-of-response-in-metastatic-melanoma2026-05-06T16:15:00Z2026-05-06T16:15:00Z https://www.onclive.com/view/transformational-utah-investment-in-artificial-intelligence-and-computing-to-advance-health-and-discovery2026-05-06T16:00:00Z2026-05-06T16:00:00Z https://www.onclive.com/view/asco-2026-breast-cancer-preview-read-up-on-the-insights-to-know-before-you-go2026-05-06T14:07:07.191Z2026-05-06T14:07:07.191Z https://www.onclive.com/view/consensus-viewpoints-offer-guidance-in-rapidly-evolving-multiple-myeloma-management2026-05-06T13:03:02.159Z2026-05-06T13:03:02.159Z https://www.onclive.com/view/comparing-approved-checkpoint-inhibitor-regimens-and-optimal-treatment-duration2026-05-06T12:05:00Z2026-05-06T12:05:00Z https://www.onclive.com/view/disease-assessment-and-mutational-testing-in-progressive-cll2026-05-06T12:04:00Z2026-05-06T12:04:00Z https://www.onclive.com/view/clinical-scenario-presentation-and-treatment-approach-for-progressive-disease2026-05-06T12:01:00Z2026-05-06T12:01:00Z https://www.onclive.com/view/four-year-follow-up-outcomes-in-dmmr-endometrial-cancer-presented-at-sgo-20262026-05-06T12:00:00Z2026-05-06T12:00:00Z https://www.onclive.com/view/dr-pant-on-the-mechanism-of-action-of-daraxonrasib-in-pdac2026-05-06T12:00:00Z2026-05-06T12:00:00Z https://www.onclive.com/view/simlukafusp-alfa-regimens-show-manageable-safety-and-activity-but-do-not-outperform-soc-in-metastatic-rcc2026-05-05T20:42:07.704Z2026-05-05T20:42:07.704Z https://www.onclive.com/view/dr-cohen-on-frontline-chemotherapy-selection-in-metastatic-pancreatic-cancer2026-05-05T20:01:49.496Z2026-05-05T20:01:49.496Z https://www.onclive.com/view/dr-pant-on-managing-toxicities-with-daraxonrasib-in-pdac2026-05-05T19:24:50.355Z2026-05-05T19:24:50.355Z https://www.onclive.com/view/hs-10504-shows-promising-activity-in-egfr-c797s-mutant-nsclc-after-tki-resistance2026-05-05T18:00:00Z2026-05-05T18:00:00Z https://www.onclive.com/view/breast-cancer-experts-preview-abstracts-to-watch-at-the-2026-esmo-breast-cancer-congress2026-05-05T16:17:51.212Z2026-05-05T16:17:51.212Z https://www.onclive.com/view/the-type-of-fat-not-the-amount-fuels-pancreatic-cancer2026-05-05T16:00:00Z2026-05-05T16:00:00Z https://www.onclive.com/view/iopofosine-i-131-follow-up-data-show-strong-efficacy-in-waldenstr-m-macroglobulinemia2026-05-05T14:24:03.485Z2026-05-05T14:24:03.485Z https://www.onclive.com/view/dr-mcgregor-on-key-end-points-of-the-strike-trial-of-tivozanib-plus-pembrolizumab-in-rcc2026-05-05T13:58:55.937Z2026-05-05T13:58:55.937Z https://www.onclive.com/view/dr-kuykendall-on-the-evolving-jak-inhibitor-and-transplant-considerations-in-myelofibrosis2026-05-05T13:00:00Z2026-05-05T13:00:00Z https://www.onclive.com/view/egfr-mutated-nsclc-molecular-reassessment-at-disease-progression2026-05-05T12:05:00Z2026-05-05T12:05:00Z https://www.onclive.com/view/coordinating-care-in-multiple-myeloma-across-practice-settings2026-05-05T12:05:00Z2026-05-05T12:05:00Z https://www.onclive.com/view/new-endometrial-targets-beyond-her22026-05-05T12:05:00Z2026-05-05T12:05:00Z https://www.onclive.com/view/new-understandings-of-treatments-end-points-and-disease-biology-expand-mcl-horizons2026-05-05T12:00:21.975Z2026-05-05T12:00:21.975Z https://www.onclive.com/view/white-blood-cell-count-as-independent-thrombotic-risk-factor-and-symptom-burden-assessment2026-05-05T12:00:00Z2026-05-05T12:00:00Z https://www.onclive.com/view/addressing-access-barriers-in-relapsed-and-refractory-multiple-myeloma2026-05-05T12:00:00Z2026-05-05T12:00:00Z https://www.onclive.com/view/egfr-mutated-nsclc-communicating-toxicity-and-treatment-burden2026-05-05T12:00:00Z2026-05-05T12:00:00Z https://www.onclive.com/view/managing-progression-after-immunotherapy-in-endometrial-cancer2026-05-05T12:00:00Z2026-05-05T12:00:00Z https://www.onclive.com/view/drs-lee-and-saxena-on-incorporating-pd-l1-expression-as-a-biomarker-in-egfr-mutated-nsclc-management2026-05-04T23:35:00Z2026-05-04T23:35:00Z https://www.onclive.com/view/metastatic-bladder-cancer-2026-update2026-05-04T23:20:00Z2026-05-04T23:20:00Z https://www.onclive.com/view/april-roundup-of-fda-approvals-in-oncology-2-decisions-to-know2026-05-04T22:29:07.307Z2026-05-04T22:29:07.307Z https://www.onclive.com/view/dr-sznol-on-overcoming-primary-and-acquired-resistance-in-metastatic-melanoma2026-05-04T22:15:00Z2026-05-04T22:15:00Z https://www.onclive.com/view/dr-gross-on-raising-awareness-for-skin-cancer-in-light-of-melanoma-monday2026-05-04T22:10:00Z2026-05-04T22:10:00Z https://www.onclive.com/view/dr-mcgregor-on-the-strike-trial-of-tivozanib-plus-pembrolizumab-in-rcc2026-05-04T17:05:09.235Z2026-05-04T17:05:09.235Z https://www.onclive.com/view/gedatolisib-based-combinations-beat-alpelisib-based-soc-in-pik3ca-mutant-hr-breast-cancer2026-05-04T16:25:06.188Z2026-05-04T16:25:06.188Z https://www.onclive.com/view/roswell-park-experts-highlight-untapped-potential-of-cdk-inhibitor-cancer-therapy2026-05-04T16:00:00Z2026-05-04T16:00:00Z https://www.onclive.com/view/pelareorep-combination-demonstrates-durable-responses-in-second-line-ras-mutant-mss-crc2026-05-04T15:06:53.251Z2026-05-04T15:06:53.251Z https://www.onclive.com/view/dr-pant-on-landmark-efficacy-data-with-daraxonrasib-in-previously-treated-metastatic-pdac2026-05-04T14:36:36.700Z2026-05-04T14:36:36.700Z https://www.onclive.com/view/fda-approves-companion-diagnostic-for-vepdegestrant-in-esr1-er-her2-negative-advanced-breast-cancer2026-05-04T14:31:05.652Z2026-05-04T14:31:05.652Z https://www.onclive.com/view/emerging-role-of-urinary-tumor-dna-utdna2026-05-04T12:05:00Z2026-05-04T12:05:00Z https://www.onclive.com/view/treatment-sequencing-and-regimen-selection-in-plgg2026-05-04T12:05:00Z2026-05-04T12:05:00Z https://www.onclive.com/view/renal-cell-carcinoma-translating-trial-data-to-real-world-practice2026-05-04T12:05:00Z2026-05-04T12:05:00Z https://www.onclive.com/view/final-perspectives-and-key-messages2026-05-04T12:00:00Z2026-05-04T12:00:00Z https://www.onclive.com/view/mri-interpretation-hemorrhage-and-multidisciplinary-monitoring-in-plgg2026-05-04T12:00:00Z2026-05-04T12:00:00Z https://www.onclive.com/view/duvelisib-yields-strong-efficacy-durable-responses-in-r-r-ptcl2026-05-04T12:00:00Z2026-05-04T12:00:00Z https://www.onclive.com/view/renal-cell-carcinoma-interpreting-cross-trial-comparisons2026-05-04T12:00:00Z2026-05-04T12:00:00Z https://www.onclive.com/view/ctdna-in-chemoradiotherapy-and-bladder-preservation2026-05-04T12:00:00Z2026-05-04T12:00:00Z https://www.onclive.com/view/five-under-5-top-oncology-videos-for-the-week-of-4-262026-05-04T00:57:00Z2026-05-04T00:57:00Z https://www.onclive.com/view/april-s-gi-monthly-rewind-key-regulatory-updates-you-may-have-missed2026-05-03T12:02:07.535Z2026-05-03T12:02:07.535Z https://www.onclive.com/view/fda-grants-rmat-designation-to-orca-q-for-high-risk-hematologic-malignancies2026-05-02T12:00:00Z2026-05-02T12:00:00Z https://www.onclive.com/view/the-oncfive-top-oncology-articles-for-the-week-of-4-262026-05-02T10:00:00Z2026-05-02T10:00:00Z https://www.onclive.com/view/fda-clears-once-daily-ruxolitinib-tablets-for-myelofibrosis-polycythemia-vera-and-gvhd2026-05-01T22:23:02.195Z2026-05-01T22:23:02.195Z https://www.onclive.com/view/fda-green-lights-expanded-access-protocol-for-daraxonrasib-in-pretreated-metastatic-pdac2026-05-01T20:03:37.506Z2026-05-01T20:03:37.506Z https://www.onclive.com/view/show-me-the-data-from-mutation-to-action-kras-as-a-therapeutic-target-in-pdac2026-05-01T19:12:09.806Z2026-05-01T19:12:09.806Z https://www.onclive.com/view/nivolumab-plus-cabozantinib-displays-real-world-efficacy-in-first-line-advanced-rcc2026-05-01T18:00:00Z2026-05-01T18:00:00Z https://www.onclive.com/view/dr-danilov-on-how-to-approach-second-line-treatment-selection-for-cll2026-05-01T17:45:00Z2026-05-01T17:45:00Z https://www.onclive.com/view/fda-flashback-breast-cancer-decisions-and-news-from-april-20262026-05-01T17:30:38.326Z2026-05-01T17:30:38.326Z https://www.onclive.com/view/dr-sznol-on-frontline-standards-of-care-in-advanced-or-metastatic-melanoma2026-05-01T17:15:00Z2026-05-01T17:15:00Z https://www.onclive.com/view/fda-approves-vepdegestrant-for-er-her2-advanced-breast-cancer-with-an-esr1-mutation2026-05-01T16:37:30.253Z2026-05-01T16:37:30.253Z https://www.onclive.com/view/dana-farber-experts-offer-perspective-on-link-between-pesticide-exposure-and-early-onset-colorectal-cancer2026-05-01T16:00:00Z2026-05-01T16:00:00Z https://www.onclive.com/view/onclive-weekly-news-quiz-5-1-2026-are-you-caught-up-on-2-fda-odac-votes-in-prostate-and-breast-cancer-2026-05-01T14:48:39.404Z2026-05-01T14:48:39.404Z https://www.onclive.com/view/dr-sumrall-on-the-current-pcnsl-treatment-paradigm2026-05-01T13:00:00Z2026-05-01T13:00:00Z https://www.onclive.com/view/thrombocytopenia-management-in-adc-therapy-platelet-thresholds-anticoagulation-safety-and-supportive-care2026-05-01T12:05:00Z2026-05-01T12:05:00Z https://www.onclive.com/view/managing-hematologic-toxicities-with-adcs-neutropenia-growth-factor-support-and-thrombocytopenia-in-breast-and-lung-cancer2026-05-01T12:00:00Z2026-05-01T12:00:00Z https://www.onclive.com/view/fes-pet-ct-reshapes-treatment-planning-in-lobular-breast-cancer-and-beyond-with-megan-kruse-md2026-05-01T03:20:00Z2026-05-01T03:20:00Z https://www.onclive.com/view/ozuriftamab-vedotin-makes-strides-toward-phase-3-analysis-in-hpv-associated-opscc2026-05-01T00:47:12.538Z2026-05-01T00:47:12.538Z https://www.onclive.com/view/dr-monk-on-pivotal-biomarkers-in-recurrent-ovarian-cancer2026-04-30T22:40:00Z2026-04-30T22:40:00Z https://www.onclive.com/view/experts-discuss-the-landscape-of-testicular-cancer-during-testicular-cancer-awareness-month2026-04-30T22:10:19.055Z2026-04-30T22:10:19.055Z https://www.onclive.com/view/dr-clinton-on-initiatives-to-improve-outcomes-for-female-patients-with-bladder-cancer2026-04-30T21:20:56.145Z2026-04-30T21:20:56.145Z https://www.onclive.com/view/fda-odac-votes-in-favor-of-risk-benefit-profile-of-capivasertib-plus-abiraterone-in-pten-deficient-mhspc2026-04-30T20:55:52.234Z2026-04-30T20:55:52.234Z https://www.onclive.com/view/dr-venkataraman-on-potential-disparities-in-access-to-cellular-therapies-in-sarcoma2026-04-30T20:23:00Z2026-04-30T20:23:00Z https://www.onclive.com/view/oncology-experts-discuss-ways-to-combat-burnout-at-busy-conferences-and-beyond2026-04-30T16:51:45.382Z2026-04-30T16:51:45.382Z https://www.onclive.com/view/blood-test-shows-promise-for-detecting-testicular-cancer-when-standard-markers-miss2026-04-30T16:00:00Z2026-04-30T16:00:00Z https://www.onclive.com/view/fda-odac-votes-against-clinical-benefit-of-switching-to-camizestrant-in-hr-breast-cancer-after-esr1-mutation-detection2026-04-30T15:44:17.563Z2026-04-30T15:44:17.563Z https://www.onclive.com/view/phase-i-data-from-the-dareon-7-trial-evaluating-obrixtamig-a-dll3-cd3-t-cell-engager-in-combination-with-platinum-based-chemotherapy-plus-etoposide-as-first-line-therapy-for-dll3-positive-neuroendocrine-carcinomas2026-04-30T15:15:55.555Z2026-04-30T15:15:55.555Z https://www.onclive.com/view/treatment-advances-in-relapsed-sclc-introduce-new-options-and-clinical-workflows-with-alissa-cooper-md2026-04-30T15:00:00Z2026-04-30T15:00:00Z https://www.onclive.com/view/cases-and-conversations-translating-ctdna-into-clinical-decisions-in-breast-cancer2026-04-30T14:29:22.906Z2026-04-30T14:29:22.906Z https://www.onclive.com/view/capivasertib-plus-abiraterone-is-effective-in-pten-deficient-mhspc2026-04-30T14:03:19.117Z2026-04-30T14:03:19.117Z https://www.onclive.com/view/five-factors-that-guide-how-i-treat-adults-with-chronic-myeloid-leukemia-in-chronic-phase2026-04-30T14:00:56.165Z2026-04-30T14:00:56.165Z https://www.onclive.com/view/dr-jones-on-the-rationale-for-comparing-crc-risk-reduction-with-glp-1-agonists-vs-aspirin2026-04-30T13:30:02.353Z2026-04-30T13:30:02.353Z https://www.onclive.com/view/fda-odac-preview-serena-6-data-for-camizestrant-in-esr1-mutated-hormone-receptor-breast-cancer-take-center-stage2026-04-30T13:54:08.037Z2026-04-30T13:05:00Z https://www.onclive.com/view/adcs-change-treatment-paradigms-and-challenge-standard-ae-management-protocols-in-tnbc-with-sara-nunnery-md-msci-and-irene-morae-kang-md2026-04-30T13:00:00Z2026-04-30T13:00:00Z https://www.onclive.com/view/kras-mutations-in-nsclc-sequencing-across-lines2026-04-30T12:05:00Z2026-04-30T12:05:00Z https://www.onclive.com/view/future-research-priorities-in-smoldering-multiple-myeloma2026-04-30T12:05:00Z2026-04-30T12:05:00Z https://www.onclive.com/view/biparatopic-her2-binding-and-the-jacob-trial-rationale-for-single-molecule-dual-epitope-targeting2026-04-30T12:05:00Z2026-04-30T12:05:00Z https://www.onclive.com/view/preliminary-data-show-clinical-activity-with-ozekibart-folfiri-in-heavily-pretreated-crc2026-04-30T12:00:00Z2026-04-30T12:00:00Z https://www.onclive.com/view/daraxonrasib-monotherapy-as-first-line-1l-treatment-for-patients-with-metastatic-pancreatic-adenocarcinoma-mpdac-2026-04-30T12:00:00Z2026-04-30T12:00:00Z https://www.onclive.com/view/interpreting-subgroup-analyses-and-real-world-evidence-in-metastatic-castration-sensitive-prostate-cancer-mcspc-2026-04-30T12:00:00Z2026-04-30T12:00:00Z https://www.onclive.com/view/panel-introduction-treatment-landscape-and-background-on-zanidatamab2026-04-30T12:00:00Z2026-04-30T12:00:00Z https://www.onclive.com/view/taletrectinib-in-tki-pretreated-patients-with-ros1-non-small-cell-lung-cancer-updated-data-from-trust-i-and-trust-ii2026-04-30T12:00:00Z2026-04-30T12:00:00Z https://www.onclive.com/view/real-world-barriers-to-early-treatment-in-smoldering-multiple-myeloma2026-04-30T12:00:00Z2026-04-30T12:00:00Z https://www.onclive.com/view/access-to-molecular-testing-across-institutions-barriers-resources-and-real-world-solutions2026-04-30T12:00:00Z2026-04-30T12:00:00Z https://www.onclive.com/view/using-real-world-evidence-to-guide-treatment-decisions-in-metastatic-castration-sensitive-prostate-cancer-mcspc-2026-04-30T12:00:00Z2026-04-30T12:00:00Z https://www.onclive.com/view/dr-clinton-on-differences-in-bladder-cancer-incidence-according-to-gender2026-04-29T22:00:48.471Z2026-04-29T22:00:48.471Z